Genomic testing for breast cancer recurrence is guiding critical treatment decision making in early‑stage breast cancer patients, and helping clinicians avoid over and under treatment.
Myriad Genetics’ EndoPredict® Breast Cancer Prognostic Test is a genomic test for breast cancer that accurately predicts the risk of breast cancer recurrence (return) up to 15 years and an individual’s benefit from chemotherapy,2,3 helping to guide key treatment decisions for every eligible woman with early-stage ER positive/HER2 negative breast cancer.
EndoPredict is the most accurate prognostic test to guide early treatment decisions, providing an individual risk of breast cancer recurrence at 10 years.1,4
Some women will benefit more from chemotherapy than others – EndoPredict provides the personalized chemobenefit for every patient to guide decision making.3
EndoPredict is the only test to predict breast cancer recurrence risk up to 15 years, helping clinicians decide if extended endocrine therapy is needed.2
Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Congress 2022 demonstrating how EndoPredict can help guide treatment decisions and avoid overtreatment for premenopausal women with ER+, HER2- early breast cancer.
EndoPredict gives important information to guide early treatment decisions for women with invasive primary breast cancer that is:
EndoPredict is the only second generation gene expression test for breast cancer validated in premenopausal AND postmenopausal women who are lymph node positive or node negative2-8 – and the first with level of evidence 1A data,9,10 for confident treatment decisions.
EndoPredict combines three factors – a molecular score, tumor size and nodal status – to give the EPclin Risk Score. The result is more prognostic information than first generation tests and assays that only measure gene expression, or clinical pathological factors alone.
The test has been developed and validated to include genes that predict both early and late recurrence (0-15 years). These improve prognostic value of EndoPredict compared with classical prognostic factors and first generation tests.1,5,6
Learn more about EndoPredict’s superior accuracy here.
The EndoPredict breast cancer prognosis test is a CE-marked in vitro diagnostic (IVD) test. It can be performed in local molecular pathology laboratories. The results are available within a few days and the test cost refund is assured for eligible patients in many countries.
EndoPredict is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.
EndoPredict is available as a CE-marked IVD kit that can be run in local molecular pathology laboratories after a comprehensive onsite training, provided by Myriad Genetics.